CPI-203

CAS No. 202591-23-9

CPI-203( —— )

Catalog No. M13155 CAS No. 202591-23-9

CPI-203 is a potent BET bromodomain inhibitor with IC50 of 37 nM for BRD4.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 In Stock
10MG 68 In Stock
25MG 108 In Stock
50MG 199 In Stock
100MG 358 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CPI-203
  • Note
    Research use only, not for human use.
  • Brief Description
    CPI-203 is a potent BET bromodomain inhibitor with IC50 of 37 nM for BRD4.
  • Description
    CPI-203 is a potent BET bromodomain inhibitor with IC50 of 37 nM for BRD4.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    BRD4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    202591-23-9
  • Formula Weight
    399.9
  • Molecular Formula
    C19H18ClN5OS
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 200 mM
  • SMILES
    CC1=C(C)C2=C(S1)N1C(C)=NN=C1C(CC(N)=O)N=C2C1=CC=C(Cl)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Devaiah BN, et al. Proc natl Acad Sci U S A. 2012, 109(18), 6927-6932.
molnova catalog
related products
  • ZM223

    ZM223 is a potent non-covalent inhibitor of NEDD8 activating enzyme (NAE).

  • PBRM1-BD2-IN-2

    PBRM1-BD2-IN-2, a selective and cell-active inhibitor of the polybromo-1 (PBRM1) bromodomain, exhibits binding affinity and inhibitory activity specifically targeting the PBRM1-BD2 domain, with Kd and IC50 values of 9.3 μM and 1.0 μM, respectively.

  • ZEN-3694

    ZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.